Wealthfront Advisers LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 16,962 shares of the medical instruments supplier's stock, valued at approximately $2,567,000.
Other large investors have also recently bought and sold shares of the company. Auto Owners Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company during the second quarter valued at $3,721,533,000. Wellington Management Group LLP boosted its stake in shares of Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after acquiring an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock valued at $769,397,000 after purchasing an additional 4,137,888 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the stock. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a report on Thursday, August 13th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Bank of America reduced their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and a consensus price target of $185.67.
Read Our Latest Stock Analysis on Becton, Dickinson and Company
Insiders Place Their Bets
In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,779 shares of company stock valued at $1,974,669 over the last quarter. Company insiders own 0.40% of the company's stock.
Becton, Dickinson and Company Stock Up 0.1%
Shares of NYSE:BDX opened at $187.79 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market cap of $51.74 billion, a price-to-earnings ratio of 56.56, a PEG ratio of 13.22 and a beta of 0.19. The stock's 50-day moving average price is $160.66 and its two-hundred day moving average price is $160.91. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $190.01.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 126.51%.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
